Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $46.6667.

A number of brokerages have issued reports on AAPG. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target on the stock. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th.

Ascentage Pharma Group International Stock Down 4.8%

Shares of NASDAQ AAPG opened at $18.56 on Tuesday. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The firm’s fifty day moving average is $23.75 and its two-hundred day moving average is $26.53. Ascentage Pharma Group International has a 52-week low of $18.56 and a 52-week high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million for the quarter. On average, analysts forecast that Ascentage Pharma Group International will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

A number of large investors have recently made changes to their positions in AAPG. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth about $96,000. ABC Arbitrage SA bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth about $204,000. UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Finally, XY Capital Ltd boosted its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.